TNF-α exacerbates SARS-CoV-2 infection by stimulating CXCL1 production from macrophages
- PMID: 39652608
- PMCID: PMC11658697
- DOI: 10.1371/journal.ppat.1012776
TNF-α exacerbates SARS-CoV-2 infection by stimulating CXCL1 production from macrophages
Abstract
Since most genetically modified mice are C57BL/6 background, a mouse-adapted SARS-CoV-2 that causes lethal infection in young C57BL/6 mice is useful for studying innate immune protection against SARS-CoV-2 infection. Here, we established two mouse-adapted SARS-CoV-2, ancestral and Delta variants, by serial passaging 80 times in C57BL/6 mice. Although young C57BL/6 mice were resistant to infection with the mouse-adapted ancestral SARS-CoV-2, the mouse-adapted SARS-CoV-2 Delta variant caused lethal infection in young C57BL/6 mice. In contrast, MyD88 and IFNAR1 KO mice exhibited resistance to lethal infection with the mouse-adapted SARS-CoV-2 Delta variant. Treatment with recombinant IFN-α/β at the time of infection protected mice from lethal infection with the mouse-adapted SARS-CoV-2 Delta variant, but intranasal administration of recombinant IFN-α/β at 2 days post infection exacerbated the disease severity following the mouse-adapted ancestral SARS-CoV-2 infection. Moreover, we showed that TNF-α amplified by type I IFN signals exacerbated the SARS-CoV-2 infection by stimulating CXCL1 production from macrophages and neutrophil recruitment into the lung tissue. Finally, we showed that intravenous administration to mice or hamsters with TNF protease inhibitor 2 alleviated the severity of SARS-CoV-2 and influenza virus infection. Our results uncover an unexpected mechanism by which type I interferon-mediated TNF-α signaling exacerbates the disease severity and will aid in the development of novel therapeutic strategies to treat respiratory virus infection and associated diseases such as influenza and COVID-19.
Copyright: © 2024 Kobayashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Bader SM, Cooney JP, Sheerin D, Taiaroa G, Harty L, Davidson KC, et al. SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates. Proc Natl Acad Sci U S A. 2023;120(32):e2301689120. Epub 2023/07/31. doi: 10.1073/pnas.2301689120 ; PubMed Central PMCID: PMC10410703. - DOI - PMC - PubMed
-
- Leist SR, Dinnon KH, 3rd, Schafer A, Tse LV, Okuda K, Hou YJ, et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020;183(4):1070–85 e12. Epub 2020/10/09. doi: 10.1016/j.cell.2020.09.050 ; PubMed Central PMCID: PMC7510428. - DOI - PMC - PubMed
-
- Gawish R, Starkl P, Pimenov L, Hladik A, Lakovits K, Oberndorfer F, et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNgamma-driven immunopathology. Elife. 2022;11. Epub 2022/01/14. doi: 10.7554/eLife.74623 ; PubMed Central PMCID: PMC8776253. - DOI - PMC - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
